Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 PM ET. A live broadcast of the event can be accessed on their website in the 'Investors' section. West has nearly 10,000 employees across 50 locations and generated over $2.15 billion in sales in 2020. The company is a trusted partner to drug developers, delivering over 40 billion components annually.
West Pharmaceutical Services has declared a third-quarter 2021 dividend of $0.17 per share, scheduled for payment on August 4, 2021, to shareholders recorded as of July 21, 2021. This dividend reflects the company's ongoing commitment to return value to its shareholders. Additionally, management will present a business overview at the Bank of America Securities 2021 Healthcare Conference on May 11, 2021, at 2:45 p.m. EDT. West generated over $2.15 billion in sales in fiscal year 2020.
West Pharmaceutical Services reported impressive Q1 2021 results with net sales of $670.7 million, a 36.5% year-over-year increase. Diluted EPS rose 101% to $1.99, while adjusted-diluted EPS climbed 103% to $2.05. The company has raised its full-year net sales guidance to $2.630 billion - $2.655 billion from a previous range of $2.500 billion - $2.525 billion. This growth is attributed to strong organic sales driven by demand for COVID-19 related products and robust performance in the Proprietary Product Segment.
West Pharmaceutical Services, a leader in injectable drug administration, will release its first-quarter 2021 financial results on April 29, 2021, before the market opens. A conference call to discuss these results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International), using Conference ID 4285757. The call will be available for live broadcast on their website and archived for later access until May 6, 2021.
West Pharmaceutical Services, traded under the ticker WST, will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 10:00 AM ET. The presentation will be accessible via a live audio webcast on their website. West is known for providing high-quality injectable solutions and services, boasting nearly 10,000 employees and generating over $2.15 billion in sales in 2020. The company is headquartered in Exton, Pennsylvania, and is included in the Standard & Poor's 500 index.
West Pharmaceutical Services, Inc. (NYSE: WST) has announced a second-quarter 2021 dividend of $0.17 per share. This dividend will be paid on May 5, 2021, to shareholders recorded as of April 21, 2021. The company, which generated over $2.15 billion in sales in fiscal year 2020, is recognized as a leading provider of injectable solutions and services. With nearly 10,000 employees globally, West plays a crucial role in ensuring the safe delivery of vital medicines.
West Pharmaceutical Services reported strong Q4 and full-year 2020 results, with Q4 net sales of $580.2 million, a 23.3% increase, and full-year net sales of $2.147 billion, up 16.7%. Q4 diluted EPS rose 53.6% to $1.29, while full-year EPS jumped 42.4% to $4.57. The company forecasts 2021 net sales between $2.500 billion and $2.525 billion and EPS of $6.00 to $6.15. Strong sales growth was driven by the Biologics and Generics segments, particularly high-value product components for COVID-19.
West Pharmaceutical Services (NYSE: WST) has announced its plan to release fourth-quarter and full-year 2020 financial results on February 18, 2021, before the market opens. A conference call will follow at 9:00 a.m. ET to discuss the results and future business expectations. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 4095168. A live broadcast and an online archive of the call will be available on the company's website.
West Pharmaceutical Services has declared a $0.17 dividend per share for Q1 2021, payable on February 3, 2021. Shareholders of record by January 20, 2021 will receive the dividend. Additionally, the Board has authorized a share repurchase program for up to 631,000 shares in 2021, aimed at enhancing shareholder value. The program will be completed by December 31, 2021. West will also present at the J.P. Morgan Healthcare Conference on January 13, 2021, offering insights into its business.
West Pharmaceutical Services, Inc. (NYSE: WST) has appointed Kimberly Banks MacKay as Senior Vice President General Counsel and Corporate Secretary, effective December 8, 2020. She succeeds George L. Miller, who will retire in February 2021. Ms. MacKay joins from The Segal Group, bringing extensive legal experience and knowledge of the regulated pharmaceutical environment, having previously held significant roles at Novartis. The leadership change aims to support West's mission in the injectable drug market, enhancing innovation and compliance.